Skip to main content

Table 3 Median time to next treatment (TNT) and overall survival (OS) according to the histological subtype and treatment setting

From: Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study

 

Median TNT/OS (months)

 

TNT1/OS1a

TNT2/OS2b

TNT3/OS3c

TNT4/OS4d

LMS

8.0/24.9

5.6/17.3

4.6/12.3

4.4/9.2

UPS

4.8/11.0

3.5/7.9

2.3/3.7

3.5/6.2

DLPS

4.4/11.8

5.1/8.8

2.4/6.0

3.2/8.5

SS

8.7/19.7

5.7/11.7

3.4/7.8

2.3/6.0

MPNST

4.1/12.5

2.8/7.0

3.6/8.0

3.7/5.4

  1. aCalculated from the date of first-line treatment onset
  2. bCalculated from the date of second-line treatment onset
  3. cCalculated from the date of third-line treatment onset
  4. dCalculated from the date of fourth-line treatment onset
  5. DLPS dedifferentiated liposarcomas, LMS leiomyosarcomas, MPNST malignant peripheral nerve sheath sarcomas, SS synovial sarcomas, UPS undifferentiated pleomorphic sarcomas